drugset / Trial / NCT06711640
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical study is to evaluate the pharmacokinetic (PK), safety, and tolerability of LUCEMYRA in adolescents age ≥12 to \<18 years old abruptly discontinuing opioid use.
Timeline
- Start
- 2025-06
- Primary completion
- 2026-01
- Completion
- 2026-02
Outcome
Outcome not reported
Stopped (Enrollment): “Study withdrawn prior to enrollment due to strategic portfolio decisions following divestiture of the investigational product.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lofexidine | Small molecule | 0.36 mg | — |
| Subject | Lofexidine | Small molecule | 0.54 mg | — |